secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-10-21T23:59:59+00:00
Accession:  0001193125-22-266722
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.03
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma draws $25M second tranche from $100M BioPharma Credit facility
----------------------------------------------------------------------------

- $25M Tranche B Loan requested Oct 21, 2022; funding expected Dec 16, 2022.
- Interest rate: 8.25% + 3-month LIBOR (floor 1.25%); matures March 2027.
- Proceeds to be used for general corporate and working capital requirements.
- Repayment in four equal quarterly payments starting after 17th quarter anniversary of Tranche A closing.
- Prepayment premiums: 3% if before 3rd anniversary, 2% if 3-4 yrs, 1% if after 4 yrs; makewhole within 2 yrs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522266722/0001193125-22-266722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522266722/d307901d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-266722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer